OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

IL-10: The Master Regulator of Immunity to Infection

(2014) Kevin N. Couper et al.   JOURNAL OF IMMUNOLOGY

Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy

(2011) Takami Sato et al.   IMMUNOLOGIC RESEARCH

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

(2011) Andreas A. Hombach et al.   INTERNATIONAL JOURNAL OF CANCER

CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation

(2011) David M Kofler et al.   MOLECULAR THERAPY

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy

(2010) John S. Bridgeman et al.   CURRENT GENE THERAPY

Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells

(2009) E. Yvon et al.   CLINICAL CANCER RESEARCH

Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity

(2009) A A Hombach et al.   GENE THERAPY

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE